Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMME40U)

Drug Name

LY-379268 Drug Info

Synonyms

LY 379268; LY-379268; CHEMBL275079; LY379268; 191471-52-0; SCHEMBL2454646; GTPL1394; (1R,4R,5S,6R)-4-Amino-2-oxabicyclo[3.1.0]hexane-4,6-dicarboxylic acid; CTK8F0567; DTXSID90436637; ZINC3952369; BDBM50074749; FCH888149; AKOS006306876; API0003234; NCGC00159572-01; LS-98795; RT-013615; LY-379,268; B7061; J-012378; 4-Amino-2-oxa-bicyclo[3.1.0]hexane-4,6-dicarboxylic acid; (1S,2R,5R,6R)-2-amino-4-oxabicyclo[3.1.0]hexane-2,6-dicarboxylic acid; (1R,4R,5S,6R)-4-Amino-2-oxa-bicyclo[3.1.0]hexane-4,6-dicarboxylic acid

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 10197984
CAS Number: CAS 191471-52-0
TTD Drug ID: DMME40U

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Metabotropic glutamate receptor 3 (mGluR3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LY404039	DMWZIRJ	Schizophrenia	6A20	Phase 3	[3]
RO-4995819	DMNTC7O	Major depressive disorder	6A70.3	Phase 2	[4]
Oleoyl-estrone	DM0RA8F	Alzheimer disease	8A20	Phase 2	[5]
MP-101	DMYCITZ	Alzheimer disease	8A20	Phase 2	[6]
BCI-838	DMRXDN3	Major depressive disorder	6A70.3	Phase 1	[7]
Pomaglumetad	DMTOLI5	Schizophrenia	6A20	Phase 1	[8]
BCI-632	DMZYCWT	Alzheimer disease	8A20	Phase 1	[9]
PMID25435285-Compound-16	DMKFX2G	N. A.	N. A.	Patented	[10]
PMID25435285-Compound-15	DMHBWNS	N. A.	N. A.	Patented	[10]
PMID25435285-Compound-20	DMG9FYH	N. A.	N. A.	Patented	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Metabotropic glutamate receptor 2 (mGluR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RO-4995819	DMNTC7O	Major depressive disorder	6A70.3	Phase 2	[4]
Oleoyl-estrone	DM0RA8F	Alzheimer disease	8A20	Phase 2	[5]
MP-101	DMYCITZ	Alzheimer disease	8A20	Phase 2	[6]
JNJ-64281802	DMNMSVX	Dengue	1D20-1D2Z	Phase 2	[11]
BCI-838	DMRXDN3	Major depressive disorder	6A70.3	Phase 1	[7]
Pomaglumetad	DMTOLI5	Schizophrenia	6A20	Phase 1	[8]
BCI-632	DMZYCWT	Alzheimer disease	8A20	Phase 1	[9]
LY-2979165	DM16IX2	Bipolar disorder	6A60	Phase 1	[12]
JNJ-42491293	DMOL9JR	Psychiatric disorder	6E8Z	Phase 1	[13]
ADX71149	DMBUOX4	Epilepsy	8A60-8A68	Phase 1	[14]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Metabotropic glutamate receptor 2 (mGluR2)	TTXJ47W	GRM2_HUMAN	Inhibitor	[2]
Metabotropic glutamate receptor 3 (mGluR3)	TT8A9EF	GRM3_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1394).
2	Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identif... J Med Chem. 2007 Jan 25;50(2):233-40.
3	Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia. Expert Opin Ther Pat. 2009 Sep;19(9):1259-75.
4	Novel glutamatergic drugs for the treatment of mood disorders. Neuropsychiatr Dis Treat. 2013; 9: 1101-1112.
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	ClinicalTrials.gov (NCT03044249) A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression. U.S. National Institutes of Health.
7	Metabotropic glutamate receptor subtype 2 (GRM2; MGLUR2); GRM3 (MGLUR3). SciBX 3(13); doi:10.1038/scibx.2010.413. April 1 2010
8	LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia. Curr Opin Investig Drugs. 2010 Jul;11(7):833-45.
9	Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists. J Med Chem. 2004 Aug 26;47(18):4570-87.
10	Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
11	Pharmacokinetic and pharmacodynamic characterisation of JNJ-40411813, a positive allosteric modulator of mGluR2, in two randomised, double-blind phase-I studies. J Psychopharmacol. 2015 Apr;29(4):414-25.
12	Annual Reports in Medicinal Chemistry. Volume 47, 2012, Page(78).
13	Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders. Nat Rev Drug Discov. 2014 Sep;13(9):692-708.
14	MGlu2 receptor-mediated modulation of conditioned avoidance behavior in rats. European journal of pharmacology. 01/2014; 727(1).